{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:49:53Z","timestamp":1783468193763,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Salivary Gland cancer (SGC) is a rare and heterogenous group of tumors. Standard therapeutic options achieve high local but poor distant control rates, especially in high-grade SGC. The aim of this monocentric study was to evaluate patterns of recurrence and its treatment options (local ablative vs. systemic) in a homogenously treated patient population with high-grade SGC after surgery and radio(chemo)therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Monocentric, retrospective study of patients with newly diagnosed high-grade salivary gland cancer. We retrospectively reviewed clinical reports from 69 patients with high-grade salivary gland cancer in a single-center audit. Survival rates were calculated using the Kaplan\u2013Meier method and prognostic variables were analyzed (univariate analysis: log-rank test; multivariate analysis: Cox regression analysis).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median time of follow-up was 31\u00a0months. After 5\u00a0years, the cumulative overall survival was 65.2%, cumulative incidence of local recurrence was 7.2%, whereas the cumulative incidence of distant metastases was 43.5% after 5\u00a0years. 30 of 69 patients developed distant metastases during the time of follow-up, especially patients with adenoid cystic carcinoma, salivary duct carcinoma, adenocarcinoma NOS and acinic cell carcinoma with high-grade transformation. The most common type of therapy therefore was chemotherapy (50%). 85.7% of patients with local ablative therapy of distant metastases show disease progression during follow-up afterwards.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>With surgery and radio-chemotherapy, a high rate of loco-regional control is reached, but over 40% of patients develop distant metastases in the further follow-up which usually present a diffuse pattern involving in a diffuse metastases. Therefore, in the future, intensified interdisciplinary combination therapies even in the first-line treatment in certain subtypes of high-grade SGC should be investigated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-021-07024-9","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T05:02:46Z","timestamp":1629954166000},"page":"2553-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["High-grade salivary gland cancer: is surgery followed by radiotherapy an adequate treatment to reach tumor control? Results from a tertiary referral centre focussing on incidence and management of distant metastases"],"prefix":"10.1007","volume":"279","author":[{"given":"Viola","family":"Freitag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lettmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mantsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina K.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Traxdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Iro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-2169","authenticated-orcid":false,"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"issue":"1","key":"7024_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-018-4578-0","volume":"18","author":"JY Jang","year":"2018","unstructured":"Jang JY et al (2018) Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1\u20132 N0 high-grade salivary gland cancer. BMC Cancer 18(1):672","journal-title":"BMC Cancer"},{"issue":"1","key":"7024_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00292-017-0407-5","volume":"39","author":"S Ihrler","year":"2018","unstructured":"Ihrler S et al (2018) Updates on tumours of the salivary glands: 2017 WHO classification. Pathologe 39(1):11\u201317","journal-title":"Pathologe"},{"issue":"1","key":"7024_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijrobp.2004.03.018","volume":"61","author":"CH Terhaard","year":"2005","unstructured":"Terhaard CH et al (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61(1):103\u2013111","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"7024_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/0360-3016(95)00122-F","volume":"32","author":"AS Garden","year":"1995","unstructured":"Garden AS et al (1995) The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32(3):619\u2013626","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7024_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-021-06652-5","author":"J von der Grun","year":"2021","unstructured":"von der Grun J et al (2021) Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. Eur Arch Otorhinolaryngol. https:\/\/doi.org\/10.1007\/s00405-021-06652-5","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"7024_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06393-x","author":"A Ruhle","year":"2020","unstructured":"Ruhle A et al (2020) Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease. Eur Arch Otorhinolaryngol. https:\/\/doi.org\/10.1007\/s00405-020-06393-x","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"7024_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00449","author":"JL Geiger","year":"2021","unstructured":"Geiger JL et al (2021) Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.00449","journal-title":"J Clin Oncol"},{"issue":"13","key":"7024_CR8","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1245\/s10434-016-5356-3","volume":"23","author":"SJ Nam","year":"2016","unstructured":"Nam SJ et al (2016) Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 23(13):4376\u20134383","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"7024_CR9","doi-asserted-by":"publisher","first-page":"E2041","DOI":"10.1002\/hed.24375","volume":"38","author":"M Haderlein","year":"2016","unstructured":"Haderlein M et al (2016) High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. Head Neck 38(Suppl 1):E2041\u2013E2048","journal-title":"Head Neck"},{"issue":"4","key":"7024_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00405-020-06205-2","volume":"278","author":"M Westergaard-Nielsen","year":"2021","unstructured":"Westergaard-Nielsen M et al (2021) Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome. Eur Arch Otorhinolaryngol 278(4):1179\u20131188","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"7024_CR11","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.18632\/oncotarget.13952","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X et al (2017) Management of salivary gland carcinomas - a review. Oncotarget 8(3):3946\u20133956","journal-title":"Oncotarget"},{"issue":"1","key":"7024_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijrobp.2006.04.014","volume":"66","author":"AM Chen","year":"2006","unstructured":"Chen AM et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66(1):152\u2013159","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"7024_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.oraloncology.2015.02.096","volume":"51","author":"YH Zeidan","year":"2015","unstructured":"Zeidan YH et al (2015) Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. Oral Oncol 51(5):438\u2013445","journal-title":"Oral Oncol"},{"issue":"3","key":"7024_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/archotol.1990.01870030054008","volume":"116","author":"JG Armstrong","year":"1990","unstructured":"Armstrong JG et al (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116(3):290\u2013293","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"7024_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.oraloncology.2015.11.023","volume":"54","author":"A Hosni","year":"2016","unstructured":"Hosni A et al (2016) Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 54:75\u201380","journal-title":"Oral Oncol"},{"issue":"8","key":"7024_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/hed.10400","volume":"26","author":"CH Terhaard","year":"2004","unstructured":"Terhaard CH et al (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26(8):681\u2013692 (discussion 692\u20133)","journal-title":"Head Neck"},{"issue":"10","key":"7024_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cncr.32792","volume":"126","author":"X Mimica","year":"2020","unstructured":"Mimica X et al (2020) Distant metastasis of salivary gland cancer: incidence, management, and outcomes. Cancer 126(10):2153\u20132162","journal-title":"Cancer"},{"issue":"7","key":"7024_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hed.23405","volume":"36","author":"M Amit","year":"2014","unstructured":"Amit M et al (2014) Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. Intern Collab Study Head Neck 36(7):998\u20131004","journal-title":"Intern Collab Study Head Neck"},{"key":"7024_CR19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4454-y","author":"S Ali","year":"2015","unstructured":"Ali S et al (2015) Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-015-4454-y","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7024_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaoto.2016.2168","volume":"142","author":"A Amini","year":"2016","unstructured":"Amini A et al (2016) Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the national cancer data base. JAMA Otolaryngol Head Neck Surg 142(11):1100\u20131110","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"7024_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/hed.24484","volume":"38","author":"MJ Mifsud","year":"2016","unstructured":"Mifsud MJ et al (2016) Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck 38(11):1628\u20131633","journal-title":"Head Neck"},{"issue":"10","key":"7024_CR22","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1093\/annonc\/mdt338","volume":"24","author":"J Cros","year":"2013","unstructured":"Cros J et al (2013) Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol 24(10):2624\u20132629","journal-title":"Ann Oncol"},{"key":"7024_CR23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2568","author":"K Wang","year":"2016","unstructured":"Wang K et al (2016) Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2568","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7024_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37(2):125\u2013134","journal-title":"J Clin Oncol"},{"issue":"4","key":"7024_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979\u2013984","journal-title":"Ann Oncol"},{"issue":"5","key":"7024_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hed.23940","volume":"38","author":"LD Locati","year":"2016","unstructured":"Locati LD et al (2016) Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38(5):724\u2013731","journal-title":"Head Neck"},{"key":"7024_CR27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0841","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ et al (2020) The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers. Oncologist. https:\/\/doi.org\/10.1634\/theoncologist.2019-0841","journal-title":"Oncologist"},{"key":"7024_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","volume":"110","author":"W van Boxtel","year":"2019","unstructured":"van Boxtel W et al (2019) Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer 110:62\u201370","journal-title":"Eur J Cancer"},{"issue":"1","key":"7024_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","volume":"43","author":"MR Pfeffer","year":"2007","unstructured":"Pfeffer MR et al (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43(1):33\u201336","journal-title":"Oral Oncol"},{"issue":"7","key":"7024_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","volume":"45","author":"LD Locati","year":"2009","unstructured":"Locati LD et al (2009) Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45(7):574\u2013578","journal-title":"Oral Oncol"},{"issue":"18","key":"7024_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V et al (2019) Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 37(18):1529\u20131537","journal-title":"J Clin Oncol"},{"issue":"4","key":"7024_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","volume":"61","author":"S Di Palma","year":"2012","unstructured":"Di Palma S et al (2012) Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 61(4):629\u2013643","journal-title":"Histopathology"},{"issue":"3","key":"7024_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00066-020-01653-5","volume":"197","author":"M Jakob","year":"2021","unstructured":"Jakob M et al (2021) Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC. Strahlenther Onkol 197(3):231\u2013245","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"7024_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00066-020-01606-y","volume":"196","author":"K Clasen","year":"2020","unstructured":"Clasen K et al (2020) PET\/MRI and genetic intrapatient heterogeneity in head and neck cancers. Strahlenther Onkol 196(6):542\u2013551","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"7024_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00066-020-01638-4","volume":"196","author":"S Tanadini-Lang","year":"2020","unstructured":"Tanadini-Lang S et al (2020) Radiomic biomarkers for head and neck squamous cell carcinoma. Strahlenther Onkol 196(10):868\u2013878","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"7024_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00066-019-01483-0","volume":"195","author":"L Cozzi","year":"2019","unstructured":"Cozzi L et al (2019) Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlenther Onkol 195(9):805\u2013818","journal-title":"Strahlenther Onkol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-021-07024-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:08:04Z","timestamp":1649218084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-021-07024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["7024"],"URL":"https:\/\/doi.org\/10.1007\/s00405-021-07024-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}